… agreements between Biogen and partners Roche and Elan are also triggered if Biogen is acquired ..... markets novel MS drug Tysabri with partner Elan and has several drug candidates in Phase ..... novel treatment for MS, Biogen and partner Elan ELN received Food and Drug Administration approval …
Elan ELN increased revenue 17% year over year to ..... Tysabri sales in 2012 (to $1.7 billion). Elan 's balance sheet continues to improve ..... Not including the firm's investments, Elan has actually established a net cash position …
Elan ( ELN ): Q1 EPS of -$0.05 misses by $0.07 . Revenue of $288M beats by $3M . Tysabri sales rose 14% to $399M, just short of $402M consensus. Shares +1.7% premarket. ( PR ) Post your comment!
… as ISTA ( ISTA ) (although it's a small cap compared to the over $16 billion of market capitalization at Valeant) and Elan ( ELN ) are a much better bet pricing wise. In particular, Teva Pharmaceuticals ( TEVA ) is trading at under $50 with Complete …
Jefferies says Elan ( ELN +6.5% ) should start moving ahead of the bapineuzumab Phase 3 data, which the firm expects in July. Jefferies estimates a 75% of FDA approval for bapineuzumab, but believes expectations are low with little being priced into shares. Post your comment!
Elan ( ELN ) CEO Kelly Martin, who planned to step down May 1, will stay on the job until data is published from late-stage clinical trials …
… maintaining our fair value estimate for Elan ELN following 2011 financials that were on ..... forecast. While the close of the sale of Elan 's specialty pharmaceutical business has ..... have reservations about the potential of Elan 's neurology portfolio beyond Tysabri …
By Jessica King Holden : News came Friday that Biogen Idec, Inc. ( BIIB ) and partner Elan Corp. ( ELN ) won FDA approval for a label change on its multiple-sclerosis drug Tysabri. Sales of the drug, which annually produces between …
By Prohost Biotech : Elan ( ELN ) was granted FDA approval of Tysabri for Multiple Sclerosis in November ..... multifocal leukoencephalopathy), two of them died. It was Biogen Idec, Elan ’s partner on Tysabri, not the FDA, which decided to withdraw …
Elan ( ELN +3.6% ) gains after Deutsche upped the shares to Buy earlier today, citing optimism over the company's pending FY12 data release for its Alzheimer’s disease treatment bapineuzumab. Post your comment!